Potency Assurance
Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-16Aug 24, 2026
ATMP Supply Chain
Maintaining Resilient Supply Chains for Advanced Therapies
Pharma's Almanac
PAO-08-26-PA-09Aug 13, 2026
Cell Therapy
NueCell Bio Launches as a New Translational Partner to Accelerate Cell Therapies from Discovery into GMP Manufacturing
NueCell Bio
PR-08-26-01Aug 5, 2026
In Vivo CAR-T
Five Companies Bringing In Vivo CAR-T Therapy Closer to the Clinic
Emma Gormlie
Nice Insight
PAO-07-26-PA-13Jul 30, 2026
Stem Cells
Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-07-26-PA-11Jul 22, 2026
In Vivo Selection
Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-14Jul 13, 2026
Genome Engineering
Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-16Jun 29, 2026
Microbiome Editing
Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-15Jun 22, 2026
Pathfinder
Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?
Nice Insight
PAO-26-PF-11Jun 12, 2026
Continuous VV
The Stepwise Future of Continuous Viral Vector Manufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-12Jun 1, 2026
Pathfinder
AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?
Nice Insight
PAO-26-PF-09May 29, 2026
Roundtable
How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?
Pharma's Almanac
PAO-05-26-RT-02May 27, 2026
HACs
Synthetic Chromosome Therapeutics: Expanding Genomic Medicine Beyond the Limits of Gene Therapy
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-02May 11, 2026
Pathfinder
CRISPR vs. Base Editing vs. Prime Editing: Which Genome Editing Technology Is Best?
Nice Insight
PAO-26-PF-05May 1, 2026
Pathfinder
AAV vs. Non-Viral Gene Delivery: Which Is Better for In Vivo Gene Therapy?
Nice Insight
PAO-26-PF-01Apr 3, 2026
Neuro CMC
Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-03Apr 3, 2026
ATMP Fill-Finish
Designing Sterile Fill-Finish Systems for the Realities of Advanced Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-26-PA-15Mar 25, 2026
Allogeneic
Allogeneic CAR Cell Therapies: The Rise of Off-the-Shelf Immunotherapy
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-02-26-NI-15Feb 19, 2026
Ultra-Small-Scale
When Commercial Manufacturing Serves Dozens, Not Thousands
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-26-NI-11Feb 13, 2026
AAV Rare Disease
Scarcity by Design: The Manufacturing Reality of AAV Gene Therapies for Rare Indications
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-26-NI-12Feb 10, 2026